EXTH-43. DIFFERENTIATED PHARMACOLOGY OF THE IMIPRIDONE ONC201, THE FIRST SELECTIVE DRD2/3 ANTAGONIST IN CLINICAL NEURO-ONCOLOGY

ONC201, founding member of the imipridone class of compounds, has demonstrated evidence of tumor shrinkage along with exceptional safety in recurrent glioblastoma patients. In this study, we identified and characterized a previously unknown binding target of ONC201. BANDIT – a machine learning-based...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neuro Oncol
Hlavní autoři: Madhukar, Neel, Prabhu, Varun Vijay, Anantharaman, Lakshmi, Sulli, Chidananda, Davidson, Edgar, Deacon, Sean, Tarapore, Rohinton, Rucker, Joseph, Charter, Neil, Doranz, Benjamin, Oster, Wolfgang, Elemento, Olivier, Free, R Benjamin, Sibley, David, Allen, Joshua E
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2017
Témata:
Abstracts
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5692326/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.335
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky